BSE filing, NSE: VIVANZA. Summary written from the filing by ALFA Finder's alert engine.
Vivanza Biosciences Ltd: key numbers
- Share price
- ₹1.54
- Market cap
- ₹6.16 Cr
- Revenue (annual)
- ₹115.9 Cr
- Net profit (annual)
- ₹0.39 Cr
- P/E (TTM)
- 13.6×Sector 45.9×
- Promoter holding
- 20.02%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivanza Biosciences Ltd
All →Vivanza Biosciences Board Meeting Date
Vivanza Biosciences has scheduled a Board meeting on November 3, 2026 to approve unaudited Q2 and H1 FY27 financial results. No other material agenda items are listed.
Vivanza Biosciences Other Announcement
Vivanza Biosciences Ltd has filed a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended September 30, 2026.
Vivanza Biosciences Annual General Meeting
Vivanza Biosciences has convened its 44th AGM on September 11, 2026 via VC/OAVM. Nine agenda items cover financial statements, director appointments, and borrowing limit approvals.
Vivanza Biosciences Annual Report
Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting for September 11, 2026. The company also released its full Annual Report for the financial year 2025-26.
Vivanza Biosciences Board Meeting Outcome
Vivanza Biosciences approved its annual reports, the convening of the 44th AGM, and various procedural resolutions including borrowing limits and related party transactions for upcoming periods.
Vivanza Biosciences Board Meeting Date
Vivanza Biosciences has scheduled a board meeting for August 17, 2026, to discuss the AGM, financial reports, and various corporate authorizations under the Companies Act.
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.